Summary
The randomized phase 3 DELOS trial was designed to evaluate idebenone, a synthetic quinone compound, in Duchenne muscular dystrophy. The data showed that idebenone was safe and well tolerated, and it significantly reduced loss of respiratory function in patients aged 10 to 18 years.
- idebenone
- Duchenne muscular dystrophy
- dystrophin deficiency
- DELOS
- respiratory failure
- peak expiratory flow
- forced vital capacity
- forced expiratory volume in 1 second
- neurology clinical trials
- © 2015 SAGE Publications
Tools
Idebenone Delays Respiratory Decline in Duchenne Muscular Dystrophy
Permalink:
Table of contents
Cited By...
- No citing articles found.